Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Covington
Johnson and Johnson
Cerilliant
Medtronic
Farmers Insurance
McKinsey
QuintilesIMS
Fish and Richardson

Generated: June 20, 2018

DrugPatentWatch Database Preview

INVANZ Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Invanz, and when can generic versions of Invanz launch?

Invanz is a drug marketed by Merck Sharp Dohme and is included in one NDA.

The generic ingredient in INVANZ is ertapenem sodium. There are eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ertapenem sodium profile page.
Drug patent expirations by year for INVANZ
Pharmacology for INVANZ
Ingredient-typeCarbapenems
Drug ClassPenem Antibacterial
Synonyms for INVANZ
(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
(4R,5S,6S)-3-(((3S,5S)-5-((m-Carboxyphenyl)carbamoyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, monosodium salt
(4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-3-({(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid sodium
(4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-3-[[(3S,5S)-5-[[(3-Carboxyphenyl)amino]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid Sodium Salt
(4R,5S,6S)-3-{[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl-4-methyl-7-oxo-, (4R,5S,6S)-
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, disodium salt (4R,5S,6S)-
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, monosodium salt, (4R,5S,6S)-
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, monosodium salt, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-monosodium salt,(4R-(3(3S*,5S*), 4alpha,5beta,6beta(R*)))
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, disodium salt, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, monosodium salt, (4R-(3(3S*,5S*), 4alpha,5beta,6beta(R*)))-
153773-82-1
153832-38-3
153832-46-3
153832-46-3 (acid)
202467-69-4 (acid)
3B1-001639
832E463
A809465
AC-1633
AC-6814
AC1L44OL
AC1L44OO
AJ-47433
AK113737
AK128849
AK142836
AKOS015895077
AKOS016014925
AKOS025401431
AKOS025402550
AN-14741
AN-14742
AN-9650
AOB6700
BC209076
BC656994
C22H24N3NaO7S
C22H25N3O7S
CHEBI:404903
CHEBI:60070
CHEMBL1232
CHEMBL1359
CS-8020
D04049
D07908
D0Q1MS
DB00303
disodium (4R,5S,6S)-3-[(3S,5S)-5-[(3-carboxylatophenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
DTXSID50165456
Ertapenem
Ertapenem (INN)
Ertapenem [INN:BAN]
Ertapenem [INN]
Ertapenem disodium
Ertapenem Disodium (85%)
Ertapenem disodium salt
ertapenem hydrochloride
ertapenem monosodium
Ertapenem monosodium, Antibiotic for Culture Media Use Only
Ertapenem sodium
Ertapenem sodium (USAN)
Ertapenem sodium [USAN:INN]
Ertapenem sodium [USAN]
Ertapenem sodium salt
FT-0667958
FT-0697739
FT-0700915
G32F6EID2H
HE069794
HE314164
HSDB 8020
HY-13625
I06-0484
Invanz (TN)
J-009050
JUZNIMUFDBIJCM-ANEDZVCMSA-N
KMVRATCHVMUJHM-SHZCTIMHSA-L
L 749
L 749345
L 749345, MK 826
L-749345
LS-181819
LS-187017
LS-187767
MFCD09475566
MK 0826
MK 826
MK-0826
MK-826
MolPort-005-935-353
MolPort-019-992-343
MolPort-023-299-459
MolPort-027-947-972
OBWHPSQEAHSXMM-HRXMHBOMSA-N
P5HEA33D9R
Q-201065
SC-18879
SC-82925
SCHEMBL102761
SCHEMBL102763
SCHEMBL34454
sodium (4R,5S,6S)-3-({(3S,5S)-5-[(3-carboxylatophenyl)carbamoyl]pyrrolidinium-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
sodium (4R,5S,6S)-3-({(3S,5S)-5-[(m-carboxylatophenyl)carbamoyl]pyrrolidinium-3-yl}sulfanyl)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
sodium (4R,5S,6S)-3-({(3S,5S)-5-[(m-carboxyphenyl)carbamoyl]-3-pyrrolidinyl}thio)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
sodium 3-((2S,4S)-4-(((4R,5S,6S)-2-carboxy-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl)thio)pyrrolidine-2-carboxamido)benzoate
sodium 3-[[(2S,4S)-4-[[(4R,5S,6S)-2-carboxy-4-methyl-6-[(1R)-1-oxidanylethyl]-7-oxidanylidene-1-azabicyclo[3.2.0]hept-2-en-3-yl]sulfanyl]pyrrolidin-2-yl]carbonylamino]benzoate
Sodium 3-[[(2S,4S)-4-[[(4R,5S,6S)-2-carboxy-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]sulfanyl]pyrrolidine-2-carbonyl]amino]benzoate
sodium 3-[[(2S,4S)-4-[[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]sulfanyl]pyrrolidine-2-carbonyl]amino]benzoate
sodium 3-[[[(2S,4S)-4-[[(4R,5S,6S)-2-carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-2-pyrrolidinyl]-oxomethyl]amino]benzoate
ST24046690
ST2406824
UNII-G32F6EID2H
UNII-P5HEA33D9R
X8147
ZD-443 sodium
ZD-4433
ZINC3918453
ZXNAQFZBWUNWJM-HRXMHBOMSA-M

US Patents and Regulatory Information for INVANZ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, IV (INFUSION) 021337-001 Nov 21, 2001 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for INVANZ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, IV (INFUSION) 021337-001 Nov 21, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, IV (INFUSION) 021337-001 Nov 21, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, IV (INFUSION) 021337-001 Nov 21, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, IV (INFUSION) 021337-001 Nov 21, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for INVANZ
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 1 g/vial ➤ Subscribe 2013-06-20

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
McKinsey
Farmers Insurance
McKesson
Mallinckrodt
UBS
Chubb
Cipla
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.